Orthobiologics in future care damages
A treatment nobody will reimburse still has a price, and the patient is the one who pays it.
When an indicated treatment is not covered, the cost does not disappear — it moves onto the plaintiff. That makes non-coverage a damages question rather than a medical one, and it changes how a future-care figure has to be built and defended.
Where does non-coverage show up in an injury case?
ONE — ALREADY INCURRED, OUT OF POCKET
The client paid for the procedure themselves. There is a receipt and no explanation-of-benefits, and it gets framed as elective self-treatment. The answer is the clinical indication documented at the time, independent of who paid.
TWO — INDICATED BUT NOT YET RECEIVED
It belongs in future care. The figure has to be built as a full out-of-pocket cost rather than a co-pay, and it has to be tied to a stated indication and an expected interval, not to an open-ended course.
THREE — DECLINED, AND CALLED A FAILURE TO MITIGATE
A plaintiff who does not pursue a treatment they cannot pay for is in a different position from one who ignored medical advice. Whether that distinction matters legally is your question. What we can document is what was recommended, when, and what the barrier was.
What makes a future-care item in a life care plan defensible?
A number in a life-care plan is only as good as the clinical reasoning attached to it. The ones that survive have five things.
- A named indication matching the region where the evidence actually sits — see the evidence by indication.
- A confirmed pain generator, usually established by diagnostic block, so the treatment is aimed at something identified rather than something suspected.
- A stated expected interval and duration rather than an unbounded series. A pre-booked course of a fixed number of injections is not how this is decided and is easy to attack.
- An explicit statement that the treatment is not covered, so the out-of-pocket basis of the figure is on the face of the record rather than discovered later.
- An alternative, including the option of not doing it. A plan with only one path in it reads as advocacy.
We do not publish prices, and a physician is not the right source for a cost figure in any event. What we supply is the indication, the interval and the clinical rationale; the costing belongs to a life-care planner or economist.
How does metabolic health change a future-care forecast?
Future care is a forecast, and a forecast needs to know what body it is forecasting for. A patient with an untreated inflammatory and metabolic load will not hold a procedural result as long as a metabolically healthy client would, which changes both the expected interval and the honest prognosis.
That is why the metabolic workup is part of this rather than a separate curiosity. See metabolic dysfunction and injury and terrain.
The boundary
Nothing on this page is legal advice, and we do not offer opinions on mitigation, collateral source or any other doctrine. Those are yours. What a treating physician can provide is a documented indication, a documented recommendation with its date, a documented barrier where one existed, and an honest prognosis.
This practice is not aligned to a side. Its obligation runs to the patient’s health and safety, which is the same reason it is not beholden to any position that would keep it from seeing what is actually there. We do not offer opinions on liability, we do not accept a referral or a review conditioned on reaching a particular conclusion, and we will say plainly when the evidence does not support the claim — whichever party was hoping otherwise.
Frequently asked questions
Will you give a dollar figure for future care?
No. We supply the indication, the expected interval and the clinical rationale; the costing is a life-care planner’s or economist’s work. No prices are published on this site.
Can a life-care plan include a treatment no insurer covers?
That is a question for you and your planner. What we can do is document that the treatment was clinically indicated and that the plan declined to fund it — two separate facts, recorded separately. See coverage is not evidence.
Does an out-of-pocket procedure look worse than a covered one?
It looks different, and the responding party will use that. The counterweight is a contemporaneous record showing the indication was established before the payment question arose.
What if the patient can never afford the treatment?
Then the honest prognosis is the one without it, and that is what goes in the record. A prognosis written around a treatment the patient will not receive is not a prognosis.
What is a life care plan in a personal injury case?
It is a forecast of the care an injured person will need, with a cost attached to each item. The costing is the work of a life-care planner or economist. The treating physician supplies the clinical part: the indication, the expected interval and duration, the rationale, and whether the treatment is covered. A number in the plan is only as good as that reasoning.
Is declining a treatment you cannot afford a failure to mitigate?
A plaintiff who does not pursue a treatment they cannot pay for is in a different position from one who ignored medical advice. Whether that distinction matters legally is the attorney’s question, not the physician’s. What this practice documents is what was recommended, when it was recommended, and what the barrier was.
Related reading
- Orthobiologics: PRP and BMAC
- A denial is a budgeting decision
- What the evidence actually says
- Future care and life-care plans
- Metabolic dysfunction and injury
Get the indication and the interval on the record
Send the diagnosis and we will state what is indicated, how often, and on what evidence — in a form a life-care planner can actually cost.
12166 Natural Bridge Rd
St. Louis, MO 63044
Monday to Friday, 8:00 a.m. to 5:00 p.m. Nothing on this page is legal advice, and nothing on it is medical advice.
Sources
- Manchikanti L, Navani R, Navani A et al. Comprehensive evidence-based guidelines for regenerative therapies in the management of chronic low back pain: 2025 update from the American Society of Interventional Pain Physicians. Pain Physician, 2025. PubMed 41481869
- Kon E et al. Platelet-rich plasma injections for the management of knee osteoarthritis: the ESSKA-ICRS consensus. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. PubMed 38961773
- Jawanda H et al. Platelet-rich plasma, bone marrow aspirate concentrate, and hyaluronic acid injections outperform corticosteroids. Arthroscopy, 2024. PubMed 38331363
- Winkler T et al. Evidence-based guidelines on orthobiologics. EFORT Open Reviews, 2025. PubMed 40459170
- Okifuji A, Hare BD. The association between chronic pain and obesity. Journal of Pain Research, 2015. PubMed 26203274